A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing ...

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly ...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab ...

Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients with Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of Systemic Therapy ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r - - Axatilimab abstracts ...

“The data being presented at EHA showcase the potential for revumenib and axatilimab to transform the treatment paradigm for patients with acute leukemia and chronic GVHD, respectively,” said ...

Clinical data for Revumenib and Axatilimab will be presented at EHA 2025, highlighting advancements in acute leukemia and chronic GVHD. Safety concerns regarding Revuforj are highlighted ...

Investing.com -- Shares of Incyte (NASDAQ: INCY) climbed 7% today after the biopharmaceutical company announced that multiple ...